AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of -0.300–0.230 for the period, compared to the consensus EPS estimate of -0.280. The company issued revenue guidance of $313.5 million-$315.5 million, compared to the consensus revenue estimate of $313.0 million.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group reduced their target price on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and an average target price of $18.67.

AngioDynamics Stock Up 2.4%

NASDAQ ANGO traded up $0.25 during trading hours on Thursday, hitting $10.42. The company’s stock had a trading volume of 154,434 shares, compared to its average volume of 568,369. The stock has a fifty day moving average of $10.83 and a 200 day moving average of $11.53. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $13.99. The firm has a market capitalization of $429.47 million, a P/E ratio of -13.91 and a beta of 0.43.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The business had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million. On average, analysts predict that AngioDynamics will post -0.37 earnings per share for the current year.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Freedom Broker initiated coverage with a Buy recommendation, providing fresh analyst interest and demand for the stock. Read More.
• Positive Sentiment: Zacks upgraded ANGO to a Rank #2 (Buy), citing improving earnings prospects — an upgrade that can lift sentiment among Zacks-following retail and quant investors. Read More.
• Positive Sentiment: Freedom Capital raised its rating to “strong-buy,” adding further bullishness from independent shops that can influence trading flows. Read More.
• Positive Sentiment: HC Wainwright materially raised near‑term and medium‑term EPS estimates: they boosted Q1 2027 (to ~$-0.05), Q2 2027 (to ~$-0.03) and raised FY2026 (to ~$-0.15) and FY2027 (to ~$-0.03) estimates — narrowing expected losses and suggesting improving fundamentals that support the upgrade momentum. Read More.
• Negative Sentiment: Canaccord Genuity trimmed its price target to $16.00 — a reduction that may limit upside expectations even though the target remains above the current trading level. Read More.

Hedge Funds Weigh In On AngioDynamics

Several large investors have recently bought and sold shares of the business. Mercer Global Advisors Inc. ADV lifted its holdings in AngioDynamics by 38.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 14,604 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 4,030 shares during the period. XTX Topco Ltd lifted its holdings in AngioDynamics by 69.6% in the fourth quarter. XTX Topco Ltd now owns 40,811 shares of the medical instruments supplier’s stock valued at $524,000 after buying an additional 16,742 shares during the period. Quadrature Capital Ltd acquired a new position in AngioDynamics in the fourth quarter valued at approximately $463,000. Engineers Gate Manager LP acquired a new position in AngioDynamics in the fourth quarter valued at approximately $204,000. Finally, AQR Capital Management LLC lifted its holdings in AngioDynamics by 222.8% in the fourth quarter. AQR Capital Management LLC now owns 225,646 shares of the medical instruments supplier’s stock valued at $2,897,000 after buying an additional 155,753 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.